COVID-19 vaccines: rapid development, implications, challenges and future prospects

Area of Science:

• Immunology
• Virology
• Public Health

Background:

• The COVID-19 pandemic has caused global health and economic crises, with no definitive treatments available.
• Vaccination is the primary strategy to control the pandemic, with numerous vaccine candidates in development.
• Accelerated development and Emergency Use Authorization (EUA) for COVID-19 vaccines raise questions.

Purpose of the Study:

• To review different types of COVID-19 vaccines and their development.
• To compare the rapid COVID-19 vaccine development timeline with traditional methods.
• To discuss challenges and future prospects related to COVID-19 vaccines.

Main Methods:

• Review of existing literature on COVID-19 vaccine development.
• Analysis of vaccine candidate numbers in preclinical and clinical stages.
• Examination of approved vaccines under Emergency Use Authorization (EUA).

Main Results:

• As of the review, 232 vaccine candidates exist, with 60 in clinical development and 9 approved under EUA globally.
• Rapid development cycles distinguish COVID-19 vaccines from traditional vaccine timelines.
• Emerging SARS-CoV-2 strains (e.g., from UK and South Africa) pose new challenges.

Conclusions:

• Safe and effective vaccine distribution is a global priority for pandemic control.
• Unanswered questions surround the accelerated COVID-19 vaccine development and EUA process.
• Addressing challenges posed by viral mutations and ensuring equitable vaccine access are critical for future prospects.